

Flexion Therapeutics Inc (FLXN) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/F9B8E14F587EN.html>

Date: November 2021

Pages: 51

Price: US\$ 125.00 (Single User License)

ID: F9B8E14F587EN

Abstracts

Flexion Therapeutics Inc (FLXN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Flexion Therapeutics Inc (Flexion) discovers, develops and commercializes pain therapies. The company's pipeline is focused on indications that include osteoarthritis knee pain, OA pain, disease modification, and acute-post operative pain. The company's marketed product includes Zilretta which is the first and only extended-release, intra-articular therapy for patients facing with osteoarthritis-related knee pains. Flexion employs its proprietary microsphere technology to combine triamcinolone acetonide (TA) with a polylactic-co-glycolic acid (PLGA) matrix for formulating Zilretta. Its pipeline product candidate FX201 is being developed for treating pain caused from osteoarthritis of the knee and FX301, a Nav1.7 inhibitor in preclinical phase indicated for the treatment of acute-post operative pain. The company markets Zilretta in the US through its own sales and marketing organization and distributors. Flexion is headquartered in Burlington, Massachusetts, the US.

Flexion Therapeutics Inc Key Recent Developments

Oct 12,2021: Pacira to acquire Flexion Therapeutics to boost non-opioid pain portfolio
Oct 01,2021: Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 04,2021: Flexion Therapeutics Reports Second-Quarter 2021 Financial Results and Recent Business **Highlights**

Jul 29,2021: Flexion Therapeutics to Report Second-Quarter 2021 Financial Results on August 4, 2021

Jul 12,2021: Flexion Therapeutics Announces Appointment of Utpal Koppikar to its Board of Directors

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the

revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Flexion Therapeutics Inc - Key Facts
Flexion Therapeutics Inc - Key Employees
Flexion Therapeutics Inc - Key Employee Biographies
Flexion Therapeutics Inc - Major Products and Services
Flexion Therapeutics Inc - History
Flexion Therapeutics Inc - Company Statement
Flexion Therapeutics Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Flexion Therapeutics Inc - Business Description
Flexion Therapeutics Inc - Corporate Strategy
Flexion Therapeutics Inc - SWOT Analysis
SWOT Analysis - Overview
Flexion Therapeutics Inc - Strengths
Flexion Therapeutics Inc - Weaknesses
Flexion Therapeutics Inc - Opportunities
Flexion Therapeutics Inc - Threats
Flexion Therapeutics Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Flexion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD

2021

Flexion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD

2021

Flexion Therapeutics Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Aug 04, 2021: Flexion Therapeutics Reports Second-Quarter 2021 Financial Results and Recent Business Highlights

Jul 29, 2021: Flexion Therapeutics to Report Second-Quarter 2021 Financial Results on August 4, 2021

Jul 12, 2021: Flexion Therapeutics Announces Appointment of Utpal Koppikar to its Board of Directors

Jun 14, 2021: Flexion Therapeutics to Present at the 2021 Raymond James Human Health Innovation Conference

Jun 09, 2021: Flexion Therapeutics Announces Appointment of William T. Andrews M.D., F.A.C.P. as Chief Medical Officer

Jun 09, 2021: Flexion Therapeutics Announces Appointment of William T. Andrews, M.D., F.A.C.P., as Chief Medical Officer

Jun 02, 2021: Flexion Therapeutics to Present at the Goldman Sachs 42nd Annual Global Healthcare Virtual Conference

May 13, 2021: Flexion Therapeutics to Present at the RBC Capital Markets 2021 Virtual Global Healthcare Conference

May 12, 2021: Flexion Therapeutics Reports First-Quarter 2021 Financial Results and Recent Business Updates

May 05, 2021: Flexion Therapeutics to Report First-Quarter 2021 Financial Results on May 12, 2021

SECTION 6 – APPENDIX

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Flexion Therapeutics Inc, Key Facts
Flexion Therapeutics Inc, Key Employees
Flexion Therapeutics Inc, Key Employee Biographies
Flexion Therapeutics Inc, Major Products and Services
Flexion Therapeutics Inc, History
Flexion Therapeutics Inc, Subsidiaries
Flexion Therapeutics Inc, Key Competitors
Flexion Therapeutics Inc, Ratios based on current share price
Flexion Therapeutics Inc, Annual Ratios
Flexion Therapeutics Inc, Annual Ratios (Cont...1)
Flexion Therapeutics Inc, Annual Ratios (Cont...2)
Flexion Therapeutics Inc, Interim Ratios
Flexion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Flexion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Flexion Therapeutics Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Flexion Therapeutics Inc, Performance Chart (2016 - 2020)

Flexion Therapeutics Inc, Ratio Charts

Flexion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD
2021

Flexion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD
2021

I would like to order

Product name: Flexion Therapeutics Inc (FLXN) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/F9B8E14F587EN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/F9B8E14F587EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970